Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition. Calcitonin gene-related peptide (CGRP ...

See the latest Eli Lilly and Co stock price (LLY:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Learn about the executive team and board of directors at Eli Lilly and Co (LLY:XNYS) and review their bios and compensation over the latest fiscal years.

View the most recent data and latest information on option chains for Eli Lilly and Company Common Stock (LLY) at Nasdaq.com.